Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study shows medical professionals use supplements

This article was originally published in The Tan Sheet

Executive Summary

A peer-reviewed study in the July 1 Nutrition Journal finds 72 percent of physicians and 89 percent of nurses use supplements, and 79 percent of physicians and 82 percent of nurses recommend them to patients. The study, which showed multivitamins were most commonly used, examined data from the Council for Responsible Nutrition's "Life...supplemented" Healthcare Professionals Impact Study (1"The Tan Sheet" Nov. 19, 2007). The authors -- CRN executive Andrew Shao, CRN past president Annette Dickinson and Ipsos Public Affairs Senior VP Nicolas Boyon -- say it may be "surprising that physicians and nurses are as likely as the general population" to use supplements "given the negative views sometimes expressed editorially in medical journals.

You may also be interested in...



Most Health Care Providers Use And Recommend Supplements – CRN Study

Results of a Council for Responsible Nutrition survey show not only are a majority of health-care providers using dietary supplements, even those who do not use them are recommending the products to patients

China’s Cosmetic Animal-Testing Exemption ‘Not A Terribly Meaningful Solution’ – PCPC

The Personal Care Products Council’s Francine Lamoriello, EVP of global strategies, discusses shortcomings of a proposed animal-testing exemption for imported general cosmetics under a key implementing regulation drafted for China’s new cosmetics oversight framework.

Waiting For Cannabidiol Guidance? US FDA Reminds Industry Of ‘Many Other Requirements’

Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel